All In Biotech

Drug Trial Radar · NCT05687266

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,350 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,350

Actual

Start

Dec 29, 2022

Primary completion

Nov 1, 2027

Study completion Nov 1, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).

Conditions

  • NSCLC

Interventions

  • Datopotamab deruxtecanDrug

    Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

  • DurvalumabDrug

    Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

  • CarboplatinDrug

    Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.

  • PembrolizumabDrug

    Intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle for a maximum of 35 cycles or 2 years (whichever occurs first).

  • CisplatinDrug

    Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.

  • PemetrexedDrug

    Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

  • PaclitaxelDrug

    Intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) by blinded independent central review (BICR) in the non-squamous TROP2 biomarker positive populationTime frame: Approximately 3 years
  2. Overall Survival (OS) in the non-squamous TROP2 biomarker positive populationTime frame: Approximately 5 years
  3. PFS by BICR in the non-squamous populationTime frame: Approximately 3 years
  4. OS in the non-squamous populationTime frame: Approximately 5 years

Locations

254 sites in 23 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Hot Springs, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Springdale, Arkansas

  • Research Site

    Fountain Valley, California

  • Research Site

    Los Angeles, California

  • Research Site

    Orange, California

  • Research Site

    Boulder, Colorado

  • Research Site

    Fort Myers, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Hinsdale, Illinois

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Bettendorf, Iowa

  • Research Site

    Iowa City, Iowa

  • Research Site

    Waukee, Iowa

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Covington, Louisiana

  • Research Site

    Duluth, Minnesota

  • Research Site

    Rochester, Minnesota

  • Research Site

    Hannibal, Missouri

  • Research Site

    Lincoln, Nebraska

  • Research Site

    Lincoln, Nebraska

  • Research Site

    Clifton Park, New York

  • Research Site

    Asheville, North Carolina

  • Research Site

    Canton, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Maumee, Ohio

  • Research Site

    Tulsa, Oklahoma

  • Research Site

    Portland, Oregon

  • Research Site

    Salem, Oregon

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    York, Pennsylvania

  • Research Site

    Watertown, South Dakota

  • Research Site

    Memphis, Tennessee

  • Research Site

    Dallas, Texas

Showing 40 of 254 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.